Here's your roundup of energy innovation news coming out of Houston. Photo via Getty Images

Houston's energy innovation ecosystem has seen a busy spring season, with startup accelerator cohorts announced, expanded corporate partnerships, and recent funding raised.

In this roundup of short stories within Houston energy innovation, a startup enters into a strategic partnership, Greentown Labs announces a new accelerator, and more.

Syzygy taps global company to lead scaling for tech development 

Syzygy has brought on a new partner that's key to its future growth and tech production. Photo via Emerson

Houston-based Syzygy Plasmonics, which has developed a light-based catalyst reactor technology that originated out of Rice University, has selected global technology and software company Emerson (NYSE: EMR) to automate electrification of chemical production processes.

The reactor technology uses light instead of thermal energy for chemical manufacturing. The all-electric production method has the opportunity to replace fossil fuel-based combustion, making energy generation more sustainable. Syzygy estimates, according to the news release, that its reactor systems could eliminate 1 gigaton of CO2 emissions by 2040.

“We are excited to advance this opportunity with Emerson not only for its automation technologies and software but also its sustainability leadership and domain expertise in chemical engineering, electrification and hydrogen production,” says Syzygy CEO Trevor Best in the release. “As we expand beyond traditional paradigms of reactor technology and launch a new way to electrify chemical manufacturing, we wanted a technology partner who can help us scale our technology efficiently, safely and reliably.”

Emerson will provide its suite of hardware, software, and services for the Syzygy modular reactors.

"Emerson is excited to collaborate with Syzygy Plasmonics on such promising technology that could have a significant impact on industries that are some of the most challenging to decarbonize," says Peter Zornio, CTO at Emerson. “This aligns with Emerson’s culture of innovation that takes on our customers’ biggest challenges.”

Greentown Labs announces applications opening for Shell accelerator

Shell is seeking energy tech companies. Photo via greentownlabs.com

Greentown Labs, a climatetech incubator co-located in Houston and Boston, has teamed up with Shell for a Greentown Go program, geared at accelerating startup-corporate partnerships, to focus on technologies for carbon utilization, storage, and traceability.

Greentown Go Make 2023 zeroing in on alternative carbon feedstocks for carbon-intensive commodities; biogenic and nature-based solutions; and solutions for carbon storage and traceability, according to a news release.

Applications are open now, and the selected startups will have access to mentorship from Shell and Greentown's networks, desk space and membership within Greentown, $15,000 in non-dilutive grant funding, and educational workshops throughout the duration of the six-month program.

“Greentown Go brings together groundbreaking climatetech startups and the corporations that can help commercialize and scale their technologies,” says Kevin T. Taylor, interim CEO and CFO at Greentown Labs, in a news release. “Every Greentown Go program aims to drive climate impact and accelerate the energy transition. We look forward to working with Shell, a long-time Greentown partner, on this important program and supporting the latest innovations in carbon utilization, storage, and traceability.”

The program will help support Shell’s strategy through the development and scaling of technologies for carbon utilization, storage, and traceability across chemicals, carbon fuels, and more.

“Collaboration to accelerate technology development is critical to developing the energy solutions we need for a low-carbon energy future, and I am excited to see what novel technologies arise from startups participating in the Greentown Go Make 2023 program,” says Ed Holgate, commercial partnerships manager at Shell.

Chevron Technology Ventures adds Canadian startup to its Catalyst Program

Motive.io ia using AI to optimize workforce training. Photo via Motive.io

Chevron Technology Ventures announced the addition of Vancouver-based Motive.io, which provides immersive training solutions that leverage virtual and augmented reality technologies, to its Catalyst program. The program seeks out and helps to grow breakthrough technologies and solutions that have the potential to disrupt the energy industry.

"We are honored and thrilled to be selected as part of Chevron Technology Ventures' Catalyst program," says Ryan Chapman, CEO of Motive.io, in a news release. "Selection for this program represents a tremendous opportunity for Motive.io to collaborate with Chevron Technology Ventures as we continue to advance our cutting-edge immersive training solutions for the energy sector."

Motive.io's technology, called the XR Management System, "aims to revolutionize how companies train their employees by providing realistic and interactive simulations that allow learners to practice their skills in a safe and controlled environment," according to a news release.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

New Houston biotech co. lands $30M for pulmonary fibrosis drug

drug money

Most of us can claim a scar or two on our bodies. But when scarring develops inside the body, it’s known as a fibrotic disorder. A freshly launched Houston company, Oorja Bio Inc., is working on a treatment that can help to repair cells and reduce the damage wrought by the growth of fibrotic tissue in patients.

Late last month, Oorja Bio hit the scene with a pair of big announcements. Not only has the company raised a $30 million Series A thanks to founding investor California-based Westlake BioPartners, but it has also already paved the way for a Phase 2 study to take place this year.

Oorja Bio received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA), allowing the company to test its treatment in patients with idiopathic pulmonary fibrosis (IPF), a scarring of the lung tissue. IPF affects more than 150,000 adults in the United States and can result in a range of symptoms from shortness of breath to organ failure and death as it progresses.

Oorja Bio’s lead drug candidate, ORJ-001, was shown in a Phase 1 in-human trial to demonstrate “therapeutically relevant exposure and favorable tolerability” in 64 healthy adult volunteers in whom it was administered daily or weekly, according to a news release. Pre-clinical studies of ORJ-001 showed durable target tissue engagement and biomarker activity in bleomycin-induced lung fibrosis.

Administered subcutaneously, ORJ-001 is intended to improve and even restore function in cells that can reduce the signaling that causes IPF. It stops advancement of IPF and also allows for tissue repair. Currently available treatments for the disease can slow the development of IPF down, but do not address the declining lung function that’s inherent in its progression.

“The clinical and preclinical results from our studies to date give us confidence that ORJ-001 represents a novel treatment approach with the potential to repair and reverse fibrosis and modify disease progression in IPF,” Dr. Janethe Pena, CMO of Oorja Bio, said in the release.

“Our team is energized to deliver on our goal of redefining the future of fibrotic diseases, beginning with ORJ-001,” CEO and founder Sujay Kango added. “As we advance ORJ-001 in the clinic, we are embracing the paradigm shift in our biological understanding of IPF pathology that aligns with the central role of the alveolar epithelium. ORJ-001 was designed with this biology in mind and may provide, for the first time, a therapeutic intervention that repairs and reverses fibrosis and promotes disease modification.”

Most patients live only three to five years following their IPF diagnosis. Soon, ORJ-001 and Oorja Bio could give them a fighting chance.

Axiom Space tops $525M in oversubscribed round, announces Swiss subsidiary

funding boost

Axiom Space tacked on an additional $175 million to a previously announced capital raise, bringing the oversubscribed round to a total of more than $525 million.

Axiom shared in February that it had secured $350 million in a financing round led by Type One Ventures and Qatar Investment Authority. In the latest release from the company, Axiom reports that Japan-based MUFG Bank Ltd. joined the round as a new investor, in addition to continued participation from existing backers.

The funding will go toward developing the company's commercial space station, known as Axiom Station, and the production of its Axiom Extravehicular Mobility Unit (AxEMU) under its NASA spacesuit contract.

“Investor interest in this round outpaced what we set out to raise, which speaks to the moment we’re in,” Jonathan Cirtain, CEO and president of Axiom Space, said in the news release. “Our partners see what is possible in low-Earth orbit, and they see who is positioned to lead it.”

Axiom announced last month that it planned to open a Japanese subsidiary July 1. Earlier this week, it also shared plans to establish Axiom Space Switzerland, a wholly owned subsidiary based in Lucerne that is also expected to begin operations this summer.

The Switzerland subsidiary aims to establish Axiom's presence in Europe and help it partner with the European Space Agency and other space organizations and companies on the continent.

“Europe is a founding leader in the creation of the commercial space economy, and Switzerland is uniquely positioned to convene the government agencies, research institutions, and industrial entities that will shape its next decade,” Cirtain added in a separate release. “Axiom Space Switzerland facilitates the scaling of development and deployment of the infrastructure that will succeed the International Space Station.”

Texas cashes in among 10 best U.S. state economies in 2026 report

State Economics

A new study gauging the success or decline in economic performance in every state has revealed Texas' economy remains stable in 2026 after it dropped out of the top five to No. 8 last year.

Texas boasts the No. 8 best state economy in the U.S. this year, according to WalletHub's annual "Best & Worst State Economies" report. The personal finance website's analysts ranked all 50 states and the District of Columbia across 28 relevant metrics to measure each state's economic activity and health status, and its "innovation potential."

Notably, Texas leads the nation for the most exports per capita in the U.S. in a five-way tie with Louisiana, Kentucky, North Dakota, and Indiana. Across the study's three main categories, Texas ranked highly for its economic activity (No. 7) and economic health (No. 11), and the state's "innovation potential" rank is the 24th best in the nation.

This is how WalletHub ranked Texas' economic performance, where No. 1 is considered the best and No. 25 is considered average:
  • No. 6 – Change in non-farm payrolls
  • No. 8 – Change in GDP
  • No. 8 – Startup activity
  • No. 11 – Annual median household income
  • No. 18 – Government surplus/deficit per capita
  • No. 21 – Percentage of jobs in high-tech industries
  • No. 30 – Unemployment rate
WalletHub previously ranked Texas one of the top three states to start a business in 2026, with Houston earning its own entrepreneurial acclaim in separate rankings of the best big cities for new businesses and for starting a career.

"U.S. economic growth depends heavily on the performance of individual states, and some contribute more than others," the report's author wrote. "For example, California, Texas, New York and Florida have economies so large that if they were countries, they would rank in the top 20 in the world."

The five states with the worst state economies in 2026 are Rhode Island (No. 47), Maine (No. 48), Louisana (No. 49), Kentucky (No. 50), and West Virginia (No. 51).

The top 10 best state economies for 2026 are:

  • No. 1 – Massachusetts
  • No. 2 – Washington
  • No. 3 – Utah
  • No. 4 – California
  • No. 5 – Delaware
  • No. 6 – North Carolina
  • No. 7 – New York
  • No. 8 – Texas
  • No. 9 – Colorado
  • No. 10 – Florida

---

This article originally appeared on CultureMap.com.